New technologies for stamping high-strength steels
Update of the EHIMI a meteorological radar monitoring tool
January 16, 2017
AMITIE: New additive manufacturing technologies for ceramic materials
January 16, 20172017
The Structural Integrity, Micromechanics and Materials Reliability Centre (CIEFMA UPC) worked with the company ROVALMA on the development of new technologies to improve the balance between efficiency and cost in hot stamping of high-strength steels, which are used to produce parts for the manufacture of vehicles that are lighter and safer.
The project is being carried out within the framework of the EUROSTARS-2programme and is part of a wider collaboration encompassing several projects.
ROVALMA S.A. is a leading technology company in the design and development of high-performance steels and other special alloys for high performance technological applications in industry, specifically in tooling and the construction of machinery and equipment. The company’s three main areas of activity are application engineering (the study of practical applications for ROVALMA’s steel products), materials development (the formulation and development of new products), and production process engineering (the development of steel manufacturing processes).
Related Projects
- The greatest losses in the viticulture sector come from pathologies caused by fungi. Botrytis cinerea has the greatest economic impact, as it attacks all the green […]
- Climate change is dramatically affecting coastal zones. Storms are altering beaches and urban installations on the coastline, producing serious damage to marine ecosystems caused by pollution.
- The use of fibre-reinforced concrete (FRC) is a significant advance for the construction industry, in the industrial sector and in underground or prefabricated construction. In most […]
- Every year, over four million patients acquire an infection associated with a hospital stay, according to the European Centre for Disease Prevention and Control and the World Health Organisation. The data indicate that the impact of these infections has led to direct or indirect mortality of 137,000 patients and a cost of seven billion euros annually.
